Equities analysts expect that Agenus Inc. (NASDAQ:AGEN) will post earnings of ($0.37) per share for the current quarter, Zacks Investment Research reports. Two analysts have made estimates for Agenus’ earnings. Agenus reported earnings per share of ($0.30) in the same quarter last year, which would suggest a negative year over year growth rate of 23.3%. The firm is scheduled to issue its next earnings report on Thursday, March 8th.
According to Zacks, analysts expect that Agenus will report full-year earnings of ($1.19) per share for the current fiscal year, with EPS estimates ranging from ($1.25) to ($1.12). For the next year, analysts anticipate that the company will report earnings of ($1.39) per share, with EPS estimates ranging from ($1.40) to ($1.37). Zacks’ earnings per share calculations are a mean average based on a survey of sell-side analysts that follow Agenus.
Agenus (NASDAQ:AGEN) last issued its quarterly earnings results on Tuesday, November 7th. The biotechnology company reported ($0.37) earnings per share (EPS) for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.37). The company had revenue of $3.40 million for the quarter, compared to analysts’ expectations of $5.91 million. The business’s quarterly revenue was down 24.4% on a year-over-year basis.
Shares of Agenus (NASDAQ AGEN) traded down $0.07 during mid-day trading on Friday, hitting $3.77. 982,700 shares of the stock traded hands, compared to its average volume of 1,190,596. The company has a quick ratio of 1.55, a current ratio of 1.55 and a debt-to-equity ratio of -2.39. Agenus has a 12 month low of $3.20 and a 12 month high of $5.45.
In other Agenus news, CEO Garo H. Armen acquired 100,000 shares of Agenus stock in a transaction that occurred on Monday, October 30th. The stock was acquired at an average cost of $3.55 per share, for a total transaction of $355,000.00. The acquisition was disclosed in a legal filing with the SEC, which is available at this link. 7.90% of the stock is currently owned by insiders.
A number of institutional investors have recently added to or reduced their stakes in AGEN. Vanguard Group Inc. grew its position in shares of Agenus by 5.2% during the 2nd quarter. Vanguard Group Inc. now owns 3,530,585 shares of the biotechnology company’s stock valued at $13,805,000 after purchasing an additional 174,162 shares in the last quarter. Artal Group S.A. grew its position in shares of Agenus by 25.0% during the 3rd quarter. Artal Group S.A. now owns 2,500,000 shares of the biotechnology company’s stock valued at $11,025,000 after purchasing an additional 500,000 shares in the last quarter. Northern Trust Corp grew its position in shares of Agenus by 4.1% during the 2nd quarter. Northern Trust Corp now owns 941,631 shares of the biotechnology company’s stock valued at $3,682,000 after purchasing an additional 37,239 shares in the last quarter. Candriam Luxembourg S.C.A. grew its position in shares of Agenus by 12.8% during the 3rd quarter. Candriam Luxembourg S.C.A. now owns 617,700 shares of the biotechnology company’s stock valued at $2,724,000 after purchasing an additional 70,000 shares in the last quarter. Finally, Geode Capital Management LLC grew its position in shares of Agenus by 5.8% during the 1st quarter. Geode Capital Management LLC now owns 554,572 shares of the biotechnology company’s stock valued at $2,090,000 after purchasing an additional 30,265 shares in the last quarter. Institutional investors and hedge funds own 37.90% of the company’s stock.
Agenus Inc (Agenus) is an immuno-oncology (I-O) company. The Company focuses on the discovery and development of therapies that engage the body’s immune system to fight cancer. It is developing a I-O portfolio driven by platforms and programs, such as antibody discovery platforms, including Retrocyte Display, SECANT yeast display and phage display technologies designed to produce human antibodies; antibody candidate programs, including checkpoint modulator (CPM) programs; vaccine programs, including Prophage, AutoSynVax and PhosPhoSynVax, and saponin-based vaccine adjuvants, principally QS-21 Stimulon adjuvant (QS-21 Stimulon).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Agenus Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agenus Inc. and related companies with MarketBeat.com's FREE daily email newsletter.